Release Date: 27/01/21 09:00 Summary: Fourth Quarter Report for period ended 31 December 2020 Price Sensitive: Yes Download Document 289.19KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%